Your session is about to expire
← Back to Search
All participants (HIV+ and HIV- drinkers) for HIV/AIDS
N/A
Waitlist Available
Led By Yan Wang, PhD
Research Sponsored by University of Florida
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 weeks
Awards & highlights
Study Summary
This study is evaluating whether a wrist-worn alcohol monitor is accurate.
Eligible Conditions
- HIV/AIDS
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Transdermal Alcohol Concentration (TAC)
Trial Design
1Treatment groups
Experimental Treatment
Group I: All participants (HIV+ and HIV- drinkers)Experimental Treatment3 Interventions
All participants were planned to complete the BACtrack Skyn biosensor in two lab sessions, and wear the Skyn biosensor for two weeks in the field. However, due to COVID, not all participants were able to complete the lab sessions.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Skyn Monitor Lab Session 2
2019
N/A
~50
Skyn Monitor Lab Session 1
2019
N/A
~50
Skyn Monitor Field Test with EMA App
2019
N/A
~50
Find a Location
Who is running the clinical trial?
University of FloridaLead Sponsor
1,340 Previous Clinical Trials
715,656 Total Patients Enrolled
National Institute on Alcohol Abuse and Alcoholism (NIAAA)NIH
799 Previous Clinical Trials
1,362,462 Total Patients Enrolled
Yan Wang, PhDPrincipal InvestigatorUniversity of Florida
8 Previous Clinical Trials
57,097 Total Patients Enrolled
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Share this study with friends
Copy Link
Messenger